costs in intraoperative changes of the surgical plan and reductions in unnecessary surgery associated with the use of PV-MRI. Results from the previous study VALUE, which showed that no patient with PV required additional imaging tests as part of a Phase IV, confirm the results obtained in the present analysis (resulting in even slightly lower cost than the total cost of diagnosis using PV-MRI). University of Groningen, Groningen, The Netherlands, 2 University of Groningen, Groningen, Groningen, The Netherlands OBJECTIVES: Cervical cancer incidence in Serbia has been identified as one of the highest in Europe, showing slow but steady increase during the last decade. Despite the National Programme for Prevention of Cervical Cancer that has recently been established, an organised Pap screening is far from full implementation. This study aims to assess the effectiveness and cost effectiveness of absolute adherence to the proposed policy compared to the current practice. METHODS: A Markov model simulating the natural history of cervical cancer was developed. Calibration was performed using country specific data, sourcing incidence and mortality from Serbian cancer registries. Accordingly, the screening algorithm incorporated in the model was based on the local guidelines. We followed a hypothetical cohort of 100,000 15-year old girls until the end of their lifetime. Subsequently, the actual cytological screening practice covering only 20% of the targeted population was compared to a scenario of absolute adherence to the national screening programme. A discount rate of 1.5% for health and 4% for cost outcomes was applied.
OBJECTIVES:
This study aimed to develop cost-effectiveness analysis of Soft Silicone Wound-Contact Dressing (SS) versus Silver Sulphadiazine (SSD) in children with partial-thickness scalds (PTS), under the perspective of Brazilian public payers. METHODS: A literature search was conducted to gather efficacy data for SS and SSD and identified one randomized controlled trial that compared median time to 100% epithelialization (MTH) for SS and SSD. These data were used to estimate clinical benefits in terms of "inpatient days avoided". The model assumed that SSD is the current practice in Brazilian public hospitals and patients are discharged at the time their wound heals. Resource use was estimated through expert panel, only direct medical costs were included in the analysis and unit costs were obtained from Brazilian official price lists. RESULTS: The randomized trial observed MTH of 10.5 and 27.6 days for SS and SSD, respectively (incremental effectiveness of -17.1 days). Evidence from smaller observational studies have reported intervals to SS change of up to 14 days, while SSD requires two changes per day. Thus, the model estimated costs for the inpatient period assuming one dressing change for SS and 28 changes for SSD. The cost per dressing change was estimated as 33BRL for SS and 23BRL for SSD and the overall treatment costs were 1,261BRL and 23BRL. SS-related incremental costs were -1228BRL indicating a cost-saving profile. Benefits in terms of reduction in length of stay were not accounted in the base case scenario. If average public hospital daily charges were included in the cost estimation, savings would reach -2209BRL. CONCLUSIONS: SS dressing has shown higher efficacy when compared to SSD, with fewer overall costs. The significant reduction in the median time to healing offset the higher unit cost by lowering the number of required changes and the total length of stay. 
PMD34 COST EFFECTIVNESS OF AMBULATORY CARDIAC MONITOR VERSUS HOLTER

OBJECTIVES:
A new ambulatory electrocardiogram (loop recorder) has been introduced in Canada to detect arrhythmias, overcoming issues of previous recorders with its capability of automatically detecting/sending electrocardiograph data and simultaneously patient activation of device during symptoms. The loop recorder is expected to have a higher diagnostic yield due to its recording capabilities and longer test period (14days) however the cost is greater than the standard of care (Holter). Cost-effectiveness was estimated for Holter versus the loop recorder for diagnosing paroxysmal or persistent atrial fibrillation in primary physician care in Ontario, Canada, from a health payer's perspective. METHODS: A probabilistic decision analytic model was constructed to estimate cost, number of cases correctly detected, and number of strokes averted due to correct detection and treatment over a 19 month period. Direct medical costs included diagnostic testing, treatment of atrial fibrillation, prevention of stroke, and treatment of stroke. Costs were expressed in 2011 Canadian dollars. One-way, multi-way and probabilistic analyses of uncertainty were conducted. Model inputs were from various sources including primary data, published literature and expert opinion. RESULTS: Average cost was estimated at $490 for Holter, and $612 for loop recorder. Average cases of atrial fibrillation correctly detected were 0.032 for Holter, and 0.058 for loop recorder. Average number of strokes averted were 0.010 for Holter and 0.018 for loop recorder. The probabilistic mean incremental cost-effectiveness ratio of loop recorder versus Holter was $2430 per additional case correctly detected and $698 per additional stroke averted. At a $20,000 willingness-to-pay threshold the probability of the loop recorder being cost effective for cases detected and strokes averted were 95.5% and 60.4% respectively. Cases detected and strokes averted were 99.3% and 92% respectively for a willingness-to-pay of $50,000. CONCLUSIONS: Cost-effectiveness analysis favours the new loop recorder compared to Holter. 
PMD35 COST-EFFECTIVENESS ANALYSIS OF THE CORAIL HIP SYSTEM FOR PRIMARY TOTAL HIP ARTHROPLASTY IN SPAIN
OBJECTIVES:
The Corail™ Hip System, a hydroxyapatite coated cementless implant, has demonstrated its high efficacy and safety for primary total hip arthroplasty (THA) for over 20 years. The objective of this work was to evaluate the cost-effectiveness of the Corail™ Hip System in comparison with other cementless hip designs (standard) in Spain. METHODS: An analytical decision-making model was constructed as a Markov model for patients who were candidates to THA. The study perspective was from the viewpoint of the Spanish National Health System (NHS). Time horizons included in the model were 10 or 20 years and lifetime. Healthcare costs associated with the compared interventions and their consequences were expressed in euro 2011. Data came from a review of the literature and was validated by local clinical experts. A discount rate of 3% was applied on costs and efficacy data. RESULTS: The use of the Corail™ Hip System for THA compared with the standard resulted in €4317 per revision avoided and €5812 per QALY gained considering a time horizon of 10 years. The result was dominant in favour of Corail™ when a time horizon of 20 years or lifetime was considered for all the scores. Corail™ provided a gain of 0.075 QALY and saved €279 versus the standard (lifetime). There were no significant differences between sexes. In the sensitivity analysis was built the best scenario for Corail™ including the worse efficacy data available for the standard and Corail™ resulted in a gain of 0.388 QALY and saved €2226 (lifetime). The probabilistic sensitivity analysis showed that Corail™ was cost-effective in 76% of cases (threshold of €30,000/QALY). CONCLUSIONS: Preliminary results showed that the Corail™ Hip System is a cost-effective option in THA compared with the rest of cementless hip trademarks available in Spain. 
PMD36 COST-EFFECTIVENESS OF THE EX-PRESS GLAUCOMA FILTRATION DEVICE IN THE NETHERLANDS
OBJECTIVES:
To compare the costs and effectiveness of the EX-PRESS glaucoma filtration device (Alcon Inc, TX) to trabeculectomy, 5 years after surgery, in primary open angle glaucoma (POAG). METHODS: Seventy-eight patients with POAG uncontrolled despite maximally-tolerated medical therapies were randomized to receive either the EX-PRESS or undergo a trabeculectomy, realized by a single surgeon. Outcomes captured over 5 years included intraocular pressure (IOP a surrogate endpoint of glaucoma progression), use of IOP lowering medications and additional eye surgeries. The economic perspective was the one of the Dutch National Health System. Patients were considered a success if they had an IOP less than or equal to the success thresholds of 15 or 18 mmHg, without IOP lowering medications, and without having undergone further glaucoma surgery. Time to failure was analyzed using a log rank test. Costs were discounted at a 4% rate. EX-PRESS cost was not included. RESULTS: The 5-year failure rate was 41% for EX-PRESS versus 69% for trabeculectomy (Pϭ0.005) using an 18 mmHg IOP target and 46% versus 77% (Pϭ0.001) for 15 mmHg. EX-PRESS patients were less likely to use medications, and among the medically treated patients, required fewer drugs. EX-PRESS eyes required less needling (2 vs 5) and less cataract surgery (5 vs. 8). Without discounting, drug savings with EX-PRESS equaled €333.86 and €107.79 for eye surgery /laser, a total of €441.65. With a 4% discounting, the figures became €310.45, €132.78 and €443.23, respectively. CONCLUSIONS: At 5 years after surgery, EX-PRESS demonstrated that it better controls IOP than trabeculectomy, resulting in savings in both IOP lowering drugs and eye surgeries. Economic benefits of the better IOP control (less disease progression, i.e. a better vision) and saving according to a lifelong time horizon will be estimated in future modelling exercises.
PMD37 COST-EFFECTIVENESS OF THE EX-PRESS GLAUCOMA FILTRATION DEVICE IN FRANCE
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